Flex Pharma adjourned the special meeting until July 12, 2019 in order to provide shareholders with more time to complete proxies and vote their shares.
Christoph Westphal is at it again. Not quite a year after stepping down from his CEO role at Flex Pharma, the serial biotech entrepreneur launched another Boston area-based company: T-Scan Therapeutics.